CN1278123C - Detecting method for blood compounding test before transfusion - Google Patents
Detecting method for blood compounding test before transfusion Download PDFInfo
- Publication number
- CN1278123C CN1278123C CN 200310104294 CN200310104294A CN1278123C CN 1278123 C CN1278123 C CN 1278123C CN 200310104294 CN200310104294 CN 200310104294 CN 200310104294 A CN200310104294 A CN 200310104294A CN 1278123 C CN1278123 C CN 1278123C
- Authority
- CN
- China
- Prior art keywords
- blood
- solution
- aqueous solution
- detection method
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention relates to a simple and rapid detection method for a blood matching experiment, which can be used for effectively detecting whether blood donor's blood is matched (or compatible) with blood recipient's blood or not before blood transfusion, and thus, the blood transfusion safety is enhanced. The method is improved on the basis of a self manual coagulation amine precess (MP). Under the condition of not needing to use a test tube or a centrifuge, a slide piece only needs to be used, and erythrocyte alloantibodies in patients' serum (or plasma) can be effectively detected. The method of the present invention is suitable for regions with deficient resources or developing countries, especially ethnic groups, wherein the frequency of K antigens on blood cells is low.
Description
Technical field
The invention relates to a kind of method of promoting circulation of blood liquid compatibility test of advancing that is used to transfuse blood.The present invention especially can be in the advance method of promoting circulation of blood liquid compatibility test of blood transfusion about a kind of hydro-extractor that need not use.
Background technology
Blood group (blood groups) is performance human individual's a feature, is a kind of performance of heredity.Said clinically blood group is meant the difference of red blood cell surface antigen structure.From in broad terms, blood group comprises the different antigen systems of blood constituent such as red blood cell, white blood cell, blood platelet, blood plasma.And the abo blood group of general normal theory, with regard to red blood cell in being meant blood with antigen type different with regard to.For example, contain A antigen on the red blood cell, be called the A type; Contain B antigen, be called Type B; Contain A and two kinds of antigens of B simultaneously, be called the AB type; What contain neither that A antigen do not contain B antigen again is called the O type.
At present human blood group system is can be divided into more than 20 kind of blood group system according to red blood cell institute with the difference pact of antigen type, and it comprises: ABO blood group system, MNS blood group system, P blood group system, Rh blood group system, Kell blood group system, Lewis blood group system, Dutty blood group system, Kidd blood group system, Diego blood group system, I blood group system ... wait (table one).And in these blood group systems, with blood transfusion relation maximum be ABO blood group system, next is other blood group system.
Mix as if the incompatible droplet of blood of blood group in two individualities is placed on the slide, red blood cell is wherein promptly assembled cluster, and this situation is called aggegation (agglutination).When the aggegation of red blood cell takes place, also be attended by haemolysis sometimes.When the incompatible blood of blood group is imported in the blood circulation, in blood vessel also same situation can take place, the red blood cell of this aggegation cluster can stop up blood capillary and haemolysis, and will damage renal tubule, the allergic reaction that also can occur together simultaneously, but its result's threat to life.
Blood transfusion is to patients' such as losing blood of causing of a variety of causes, anaemia, low blood pressure, low protoheme a kind of important medical measure and guarantees important means that some operations are smooth.Timely and correct blood transfusion often can make critically ill patient reach the effect of coming back to life.But the blood transfusion of mistake also can be captured patient's life.Import the blood of incompatible blood group,, can produce anaphylactic shock or the serious concurrent acute renal failure of hemolytic reaction and death as untimely discovery.
1901 the moral stainer (Landsteiner) found first blood group system, i.e. from then on ABO blood group system is the human secret of having opened blood group, and makes blood transfusion become the higher clinical treatment means of security.When preparing blood transfusion, must guarantee that at first blood donor and receptor's abo blood group is harmonious, because the incompatible blood transfusion of this system often causes serious reaction.For white people, the women of childbearing age and the patient that need transfuse blood repeatedly also must make blood donor and receptor's Rh blood group be harmonious, to avoid the antibody of receptor at the anti-Rh of the responsive back generation of quilt.
Even between the identical people of ABO system blood group, transfuse blood clinically, before blood transfusion, must carry out cross match blood test (cross-match test).Whether like this, not only can check blood group determination wrong, also can find in their red blood cell or serum, other is enough to cause the antigen or the antibody of erythrocyte agglutination reaction whether also some.
The most important thing is in the cross matching that abo blood group cooperates, essential abo blood group is identical, and cross matching does not have aggegation and could transfuse blood.Known cross matching method is to adopt room temperature salt solution blood matching, the major defect of this method is to check out the complete antibody that does not match, and can not check out the incomplete antibody that do not match, so only can satisfy most of blood donor's abo blood group match requirement.And the antibody of other blood group system except that the ABO system or repeatedly to accept antibody overwhelming majority that the women of blood transfusion patient and multiple pregnancies produces be incomplete antibody, the difficult generation of red blood cell aggegation in brine media.For checking out that the incomplete antibody common method has anti-human globulin method, protease method and colloidal medium method etc., also there are some shortcomings in these methods.For transfusion safety and easy to operate, must improvement match method.
In recent years the reagent with cohesion amine (Polybrene) preparation that proposes can be checked out the antibody of complete antibody and two kinds of character of incomplete antibody, and can find to cause most antibody of hemolytic blood transfusion reaction, this kind detection method is called as manual cohesion amine method (Manual Polybrene).Cohesion amine is a kind of multivalent cation amino polymer, and it can cause normocytic reversibility aggegation, if connected together by the red blood cell of antibody sensitized and cohesion amine, irreversible aggegation will take place.
Most developed country has imported needs to use the method that detects before the standardization blood transfusion of special reagent and equipment (for example, antiglobulin serum, hydro-extractor etc.).Yet these equipment but are difficult for obtaining concerning backward country, or can't buy because of selling at exorbitant prices.Therefore, for these developing countries or backward country, it is very important that exploitation need not used the running program of the compatibility test of hydro-extractor or expensive reagent.
The present invention promptly is devoted to provide a kind of simpler than the operation of manual cohesion amine method at this, and need not use the method for expensive reagent and hydro-extractor, has the antibody of importance clinically in the blood effectively to detect.
Summary of the invention
Purpose of the present invention, providing a kind of expensive reagent and hydro-extractor of need not using can be in the advance method of promoting circulation of blood liquid compatibility test of blood transfusion.
Another object of the present invention provides a kind of operating personnel and only need accept the method that minimum training can be carried out the blood compatibility test.
Another purpose of the present invention provides method simply a kind of and the preceding blood compatibility test of blood transfusion fast.
Proposed by the invention in the advance method of promoting circulation of blood liquid compatibility test of blood transfusion, be that improvement is from manual cohesion amine method (Manual Polybrene, MP), the detection mode of test tube and hydro-extractor will originally be needed, change with a carrier (for example, microslide) and replace, to obtain a kind of quick and easy blood compatibility test method, referred to herein as slide cohesion amine method (Slide Polybrene, SP).
Its method is to leave standstill after the cohesion amine aqueous solution mixes by using a carrier (for example, microslide), add low ionic forces solution, patients serum to be measured (or blood plasma) and blood donor's blood cell (or antibody screening blood cell) back in regular turn and mix on this carrier, adding.Appearance erythrocyte agglutination phenomenon that at this moment can be very fast.Afterwards, add aaerosol solution more again, the aggegation meeting that is caused by cohesion amine after rocking disperses once again; Then can not be separated by the caused aggegation of antibody, and the product that this aggegation is produced, can be immediately and easily by naked eyes or magnifier (if necessary time) observed to.
Red blood cell is by action of centrifugal force it to be abutted against together in the manual cohesion amine method, strengthens its hemagglutination effect thus.Yet red blood cell is to flock together by the positive charge effect of condensing amine reagent in slide cohesion amine method, to cause non-specific erythrocyte agglutination.
The present invention will be by being described further with reference to following embodiment, and these embodiment do not limit the content that disclose front of the present invention.Be familiar with skill person of the present invention, can do some improvement and modify, but still do not break away from category of the present invention.
Embodiment
According to a kind of slide cohesion amine method proposed by the invention, it detects step can be distinguished into three phases haply, comprises sensitization stage (sensitization phase), cohesion amine to assemble stage (Polybreneaggregation phase) and suspension stages (resuspension phase) again.
Sensitization stage wherein, be to comprise low ionic forces solution (is for example added a carrier of being ready in advance, microslide) on, and then having dripped on this carrier has low solion place to add test serum (or blood plasma) and red blood cell [antibody screening blood cell (antibody screening cells) or blood donor's blood cell] brine solution [or 10 μ l Packed Red Blood Cells (packed RBCs)].These reagent can be mixed it by stirring rod, then leave standstill under room temperature 0.5～5 minute, are preferably 1～2 minute.
Cohesion amine is assembled the stage, is to comprise in the mixed liquor on the aforementioned slide of cohesion amine reaction solution (working solution) adding, and with paint daubs it is mixed, and then leaves standstill 0.5～5 minute under room temperature (about 22 ℃), is preferably 1～3 minute.The red blood cell clustering phenomena begins after 30 seconds to occur in adding the cohesion amine aqueous solution usually, and finishes in 1 minute;
Suspension stages again, the aaerosol solution again that comprises adds in the reagent of above-mentioned slide, shakes about 8～120 seconds of this slide with the have gentle hands jog again, is preferably 10～60 seconds, is disperseed up to any non-specific aggregation that is caused by cohesion amine.Really then can not be separated, and can arrive for naked eyes are observed immediately by the caused gathering of antibody.For fainter reaction, this gathering product can be observed by amplifier.Can obtain the result that detects thus fast, and after adding again suspending liquid, need not surpass 3 minutes usually and can not obtain testing result.
With regard to daily quality control should comprise a faint reaction anti--E or anti--D be as the positive control group, and inserts AB type serum as the negative control group.
Aforesaid low ionic forces solution, test serum, red blood cell brine solution and the volume ratio of the use amount of aaerosol solution again, so that the use amount of aaerosol solution was 1 parts by volume again, the use amount of low ionic forces solution was 1.5～8 parts by volume, is preferably 2～4 parts by volume; And the use amount of test serum is 1～5 parts by volume, is preferably 1.5～2.5 parts by volume; The use amount of red blood cell brine solution is 0.5～3 parts by volume, is preferably 0.75～1.5 parts by volume.
Aforesaid low ionic forces solution can be by soluble in water prepared with glucose and disodium EDTA (disodiumEDTA).For example, 25 gram glucose and 1 gram disodium EDTA are dissolved in 500 ml distilled waters.
Aforesaid red blood cell brine solution is allocated with 0.9% normal saline solution to form, and its concentration is 15～25%, is preferably 18～22%.
Aforesaid cohesion amine reaction solution is formulated with normal saline solution institute, and its concentration is preferably 0.1～0.15%.Its configuration and store method can be mixed with 10% storage solutions (stock solution) refrigerated storage by 1 gram cohesion amine and 10 milliliter of 0.9% normal saline solution.When to be used, be mixed with the reaction solution of desired concn again with 0.9% normal saline solution.
Aforesaid aaerosol solution again is that the trisodium citrate aqueous solution with 0.3～0.5M mixes prepared with 5% D/W.The mixed volume ratio of aforesaid trisodium citrate aqueous solution and D/W is preferably 1～2: 1.
Embodiment one
Condense the sensitivity that the amine method detects with slide
For detecting slide cohesion amine method for the sensitivity that detects alloantibody (alloantibodies) not of the same race.Comprise anti--E, anti--" Mi at this employed alloantibody
a", anti--D, anti--K, anti--Jk
a, anti--Jk
b, anti--Di
a, anti--Fy
aAnd anti-Fy
b, and be taken from " the international immune blood exchange of serum, cell and rare blood tissue (Serum, Cells and Rare Fluids International ImmunohematologyExchange Group, SCARF) " the give antibody rare in Taiwan.
At first, prior to being about the oval overflow ring of 3 * 1.5 centimeters sizes with the wax crayon size of drawing on the microslide, reagent overflows this scope in the testing process in order to avoid, and causes the deviation of testing result.
Afterwards, three (every about 50 μ l) low ionic forces solution is added in the microslide, and then add two test serums and one 20% antibody screening blood cell brine solution, after with paint daubs it being mixed, under room temperature, left standstill about 1 minute.
Add one 0.1% cohesion amine reaction solution in the reagent on aforementioned microslide, and it is mixed, then under room temperature, left standstill 1 minute with paint daubs.
One aaerosol solution is again added in the reagent on the above-mentioned microslide, shake 10 seconds of this slide with the have gentle hands jog again, the non-specific aggregation that is caused by cohesion amine is scatter.At last, again with the erythrocytic aggegation result of visual inspection.
The mensuration mode of serum antibody power valency is to utilize semiquantitative mode to measure, its be with the dilute serum of doubling dilution gained again with a certain amount of blood cell effect, at last can represent the power valency of antibody with the highly diluted multiple of red blood cell generation agglutinating reaction.
Using the thinning agent of measuring as antibody power valency is 3% albumin common salt aqueous solution (bovine serum albumin(BSA) is available from U.S. Sigma chemical company).
Comparing embodiment one
To condense the sensitivity that the amine method detects by hand
Use with embodiment one in identical antibody screening blood cell, be deployed into 3% concentration with 0.9% normal saline solution.
2 test serums and 1 3% antibody screening blood cell are added in the test tube, shake mixing afterwards.
Add 0.6 milliliter low ionic forces solution (LIM) in each test tube, after the mixing, left standstill 1 minute.In above-mentioned test tube, add 2 (about 0.1 milliliters) 0.05% cohesion amine aqueous solution again, mix, left standstill 15 seconds.
With above-mentioned mixed liquor with 3, centrifugal 10 seconds of the rotating speed of 400rpm.Remove supernatant.
The suspending liquid again that adds 2 (0.1 milliliters), 10 seconds of mixing of mitigation.Be poured on the slide and in 3 minutes, with the naked eye have or not agglutination phenomenon (in 10 seconds) if the polymerization that cohesion amine causes should be able to scatter, if the aggegation that antigen-antibody causes then can not separate with microscopic examination.
Test serum is also measured with above-mentioned method with doubling dilution dilution and with a certain amount of red blood cell effect, with determine can with the highly diluted multiple of red blood cell generation agglutinating reaction.
Comparing embodiment two
The sensitivity that detects with indirect antiglobulin method
In test tube, add two of test serums, add afterwards 1 with comparing embodiment one in 3% identical antibody screening blood cell, with 3, centrifugal 15 seconds of 400rpm rotating speed, shake out, add 2 of bovine albumin (BovineAlbumin) solution, under 37 ℃, left standstill 15～30 minutes.After normal saline solution cleaning 3～4 times, remove supernatant.
Add the 2 anti-human body globulin of multivalence reagent, again with 3, centrifugal 15 seconds of 400rpm has or not agglutination phenomenon with naked eyes or microscopic examination after mixing.If it is aggegation is arranged, then positive.
Test serum is also measured with above-mentioned method with doubling dilution dilution and with a certain amount of red blood cell effect, with determine can with the highly diluted multiple of red blood cell generation agglutinating reaction.
Different blood serum samples in embodiment one, comparing embodiment one and the comparing embodiment two, respectively through doubling dilution with different detection methods, mensuration can with the highly diluted multiple of red blood cell generation agglutinating reaction, its measurement result is shown in table two.
Comprehensive embodiment one, comparing embodiment one and comparing embodiment two, by anti-in detecting as can be seen in the table two-during E, slide cohesion amine method (SP) and manual cohesion amine method (MP) antiglobulin method (IAT) indirectly have higher sensitivity.And indirect antiglobulin rule condenses the amine method than slide and manual cohesion amine method resists-" Mi in detection
a" ,-K ,-Jk
aAnd-Jk
bThe time higher sensitivity arranged.
Embodiment two
Slide cohesion amine method is to the recall rate of different alloantibodies
For testing the recall rate of different alloantibodies (alloantibodies), comprise anti--" Mi at this employed alloantibody
a" (23 example), anti--E (8 example), anti--D (5 example), anti--C (1 example), anti--Jk
a,-Jk
bAnd-Jk3 (totally 8 examples), anti--Kp
b(2 example), anti--Di
aAnd-Di
b(totally 6 examples), anti--S (1 example), anti--M (4 example), anti--P1 (2 example), anti--Le
aAnd-Le
b(totally 2 examples), anti--A (10 example), anti--B (10 example), anti--H (13 example) and anti--I (2 example), totally 85 examples, partial antibody is to be taken from " the immune blood exchange tissue in serum, cell and the rare blood world (SCARF) ".
The antibody screening blood cell that will contain aforementioned alloantibody antibody is tested with the detection method described in the embodiment one, but without the doubling dilution dilution, detects tested sample aggegation situation with naked eyes, and it the results are shown in table three.
Comparing embodiment three
Manual cohesion amine method is to the recall rate of different alloantibody antibody
With employed 85 routine alloantibody antibody among the embodiment two, to test with the method in the comparing embodiment one, but, detect tested sample aggegation situation with naked eyes without the doubling dilution dilution, it the results are shown in table three.
Comparing embodiment four
Antiglobulin method is to the recall rate of different alloantibody antibody indirectly
With the 85 routine alloantibody antibody of being tested among the embodiment two, to test with the method in the comparing embodiment two, but, detect tested sample aggegation situation with naked eyes without the doubling dilution dilution, it the results are shown in table three.
Comprehensive embodiment two, comparing embodiment three and comparing embodiment four are by learning in the table three that slide cohesion amine method can be from 23 anti--" Mi
a" detect 21 in the sample, in 8 anti--E samples, detect 7.In addition, slide cohesion amine method also can be rapidly and is detected blood group incompatible in the ABO blood group system completely.In addition, slide cohesion amine method also can detect fast for other important clinically alloantibody, and the alloantibody that these are important clinically also comprises the antibody that resists Kidd and Diego blood group system antigen.
On the other hand, in 85 alloantibodies of taking from sufferer, there have 74 antibody to can be slide cohesion amine method after after testing to be measured, comprises 10 anti--A and 10 anti--B.And anti--Kp
aOnly can be measured by indirect antiglobulin method.
Though two kinds of cohesion amine methods all have the difficult shortcoming that records the antibody of Kell blood group system.Yet, the frequency very low (near 0%) that K antigen occurs in people's the group in the Orient, therefore the importance on clinical medicine is little.
The result of comprehensive embodiment one and embodiment two shows that slide cohesion amine method can detect the important clinically alloantibody of major part, particularly anti--E and anti--" Mi
a".These two kinds of antibody are to be important on the clinical medicine of Taiwan and modal alloantibody, and also have similar clinical importance in other south east asia.In the white MNS blood group system, the MiIII blood group is to belong to rare blood type, yet the frequency that occurs in Taiwan is 7.3%, and wherein the ratio that occurs with the Taiwan aboriginal is up to the hat in the world.In per approximately 200 people in Taiwan, have a people have can with the reaction of the phenotypic red blood cell of MiIII anti--" Mi
a" antibody, so the employed antibody screening of Taiwan blood bank operation blood cell must contain the phenotypic red blood cell of MiIII, the response class of its rejection and abo blood group is seemingly when inputing blood by mistake.
Other alloantibody, for example resist-D ,-K ,-Jk
a,-Jk
b,-Fy
aAnd-Fy
bIt is measured also to can be slide cohesion amine method, and its sensitivity is close with manual cohesion amine method.Though slide cohesion amine method (and manual cohesion amine method) is anti-in detecting-during K, be low than the sensitivity of indirect antiglobulin method.But, therefore can expect that the incidence of anti--K should be quite low because the sufferer of most south east asia and tax blood person are all the K antigen negative.Actual example, Taiwan only find over 20 years in the past an example can with the antigen reactive antibody of Kell blood group system.Therefore,, use the antibody program of Sensitive Detection Kell blood group system to south east asia, seemingly unwanted in the blood compatibility test program of routine.
In sum, slide cohesion amine method is a kind of being exceedingly fast (about five minutes), cheap (reagent that detects usefulness is easy to preparation, and can be in the laboratory own the preparation), and the detection method of easy operating.Operating personnel only need the training about a day can be competent at this testing.Therefore, in the less country of resource, especially the cooperation of ABO blood group system is mainly done in the compatibility test before the blood transfusion, uses slide cohesion amine method, can improve transfusion safety significantly.In these countries, many important antibody that are detected not yet clinically also can be detected thus.
Blood transfusion work in developing country not only lacks hydro-extractor, also lacks enough funds simultaneously and buys reagent and train new personnel.In these countries, can select to use slide cohesion amine method, be used for detecting to improve the safety of blood transfusion sufferer before the conventional blood transfusion.
Show a part of known blood group system and specific antibody thereof
| Blood group system | Antibody | Hemolytic blood transfusion reaction |
| ABO | Anti-A, anti-B | Have |
| Anti-H | Seldom | |
| Rh | Anti-C, anti-c, anti-D, anti-E, anti-e | Have |
| MNS | Anti-M, anti-N, anti-S, anti-s | Seldom |
| P | Anti-P 1 | Do not have |
| I | Anti-I | Have |
| Diego | Anti-Di a, anti-Di b | Have |
| Kell | Anti-K | Have |
| Lewis | Anti-Le a, anti-Le b | Have |
| Duffy | Anti-Fy a, anti-Fy b | Have |
| Kidd | Anti-Jk a, anti-Jk b, anti-Jk3 | Have |
Table two detects the comparison of the power valency of alloantibody with slide cohesion amine method (sP), manual cohesion amine method (MP) and indirect antiglobulin method (IAT)
Remarks: *: the commercial monoclonal antibody of checking and approving for Food and Drug Administration (FDA) (monoclonal antibodie)
| Method | Anti-one | ||||||||||||||||
| E | E | E | E | E | E | E* | “Mi a” | “Mi a” | “Mi a” | “Mi a” | “Mi a” | ||||||
| Slide cohesion amine method | 1 | 4 | 8 | 16 | 128 | 512 | 200 | 1 | 2 | 2 | 4 | 8 | |||||
| Manual cohesion amine method | 1 | 8 | 128 | 64 | 1024 | 2048 | 1600 | 2 | 2 | 4 | 16 | 8 | |||||
| Indirect antiglobulin method | 1 | 8 | 2 | 1 | 512 | 256 | 200 | 1 | 4 | 16 | 64 | 32 | |||||
| Method | Anti-one | ||||||||||||||||
| D* | K # | K # | JK a# | JP b# | JK b# | Di a# | Fy a# | Fy b# | Fy b | ||||||||
| Slide cohesion amine method | 1600 | 2 | 16 | 2 | 4 | 16 | 2 | 4 | 4 | 1 | |||||||
| Manual cohesion amine method | 6400 | 1 | 16 | 1 | 4 | 16 | 16 | 64 | 16 | 16 | |||||||
| Indirect antiglobulin method | 3200 | 64 | 512 | 4 | 8 | 32 | 4 | 128 | 8 | 4 | |||||||
#: the commercial antiserum of checking and approving for Food and Drug Administration (FDA).
The different detection methods of table three can detected sufferer number to different alloantibody institutes
| Anti-- | The sufferer number | Slide cohesion amine method | Manual cohesion amine method | Indirect antiglobulin method |
| “Mi a” | 23 | 21 | 23 | 23 |
| E | 8 | 7 | 8 | 7 |
| D | 5 | 5 | 5 | 5 |
| C | 1 | 1 | 1 | 1 |
| JK a.Jk a.Jk3 | 8 | 5 | 8 | 8 |
| Kp b | 2 | 0 | 0 | 2 |
| Di a.Di b | 6 | 3 | 6 | 6 |
| S | 1 | 1 | 1 | 1 |
| M | 4 | 4 | 4 | 2 |
| P1 | 2 | 2 | 2 | 0 |
| Le a.Le b | 2 | 2 | 2 | 1 |
| A | 10 | 10 | 10 | 10 |
| B | 10 | 10 | 10 | 10 |
| H * | 1 | 1 | 1 | 1 |
| I | 2 | 2 | 2 | 0 |
| Sum | 85 | 74 | 83 | 77 |
Remarks: *: be Bombay phenotype (Bombay phenotype)
Claims (7)
1. the detection method of a blood compatibility test, it is made up of the following step:
(A) take a carrier;
(B) add low ionic forces solution on this carrier, test serum or blood plasma, and red blood cell common salt aqueous solution left standstill 1～2 minute after mixing;
(C) on this carrier, add cohesion amine common salt aqueous solution again, after mixing, left standstill 1～3 minute;
(D) in this carrier, add aaerosol solution more again, jog 10～60 seconds;
(E) situation of observation erythrocyte agglutination,
Wherein the concentration of this red blood cell common salt aqueous solution is 18～22%, and the concentration of this cohesion amine common salt aqueous solution is 0.1～0.15%.
2. detection method as claimed in claim 1, wherein should hang down ionic forces solution, this test serum or blood plasma, this red blood cell common salt aqueous solution, and the use amount that should condense the amine common salt aqueous solution, when the use amount of aaerosol solution was 1 parts by volume again with this, the use amount of this low ionic forces solution was 2～4 parts by volume; The use amount of this test serum or blood plasma is 1.5～2.5 parts by volume; The use amount of this red blood cell brine solution is 0.75～1.5 parts by volume.
3. detection method as claimed in claim 2, wherein this 1 parts by volume is to be 20～200 microlitres.
4. detection method as claimed in claim 1, wherein the low ionic forces solution of this in this step (B) be to be dissolved in the distilled water prepared with glucose and disodium EDTA.
5. detection method as claimed in claim 1, wherein this in this step (D) again suspending liquid to be that trisodium citrate aqueous solution with 0.3～0.5M mixes with 5% D/W prepared, wherein the volumetric mixture ratio of this trisodium citrate aqueous solution and this D/W is 1～2: 1.
6. detection method as claimed in claim 1, wherein this carrier in this step (A) is a microslide.
7. as claim 1 or 6 described detection methods, an overflow ring is set further on this carrier wherein.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310104294 CN1278123C (en) | 2003-11-06 | 2003-11-06 | Detecting method for blood compounding test before transfusion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310104294 CN1278123C (en) | 2003-11-06 | 2003-11-06 | Detecting method for blood compounding test before transfusion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1614424A CN1614424A (en) | 2005-05-11 |
| CN1278123C true CN1278123C (en) | 2006-10-04 |
Family
ID=34756951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310104294 Expired - Fee Related CN1278123C (en) | 2003-11-06 | 2003-11-06 | Detecting method for blood compounding test before transfusion |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1278123C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101644712A (en) * | 2008-08-07 | 2010-02-10 | 刘景春 | Technique for detection by using polybrene microplate before blood transfusion |
| TWI475229B (en) * | 2012-05-18 | 2015-03-01 | Mackay Memorial Hospital | A reagent group for transfusion test and its test method |
| CN103364571B (en) * | 2013-06-24 | 2016-01-20 | 英科新创(厦门)科技有限公司 | A kind of cross matching detection method and examination bar |
| CN108593942B (en) * | 2018-04-17 | 2020-09-08 | 杭州电子科技大学 | Cross blood matching method |
-
2003
- 2003-11-06 CN CN 200310104294 patent/CN1278123C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1614424A (en) | 2005-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI475229B (en) | A reagent group for transfusion test and its test method | |
| CN1982894B (en) | Simultaneous determination of forward and reverse ABO blood group | |
| Kang et al. | Comparison of ABO antibody titers on the basis of the antibody detection method used | |
| CN102175877A (en) | Method for trace, fast and accurate detection of human erythrocyte antigen and antibodies in serum | |
| US8889368B2 (en) | Use of ferrofluids for phenotyping blood and related applications | |
| CN102435756A (en) | Preparation method of ABO and RhD blood typing detection card | |
| CN102879560A (en) | Method for accurately and rapidly detecting antigens and antibodies in human serum in trace mode | |
| Ercan et al. | 70-year old female patient with mismatch between hematocrit and hemoglobin values: the effects of cold agglutinin on complete blood count | |
| US20070218515A1 (en) | Method and kits for the determination of the antigens on the red blood cells and antibodies of serum | |
| CN1904618A (en) | Method of implementing erythrocyte blood group antigen detection on haemocyte analysis instrument | |
| CN1278123C (en) | Detecting method for blood compounding test before transfusion | |
| Dubey et al. | Validation of a hemoglobinometer for use in outdoor blood donation camps | |
| US20080166701A1 (en) | Immunoassay Method and Immunoassay Kit to Be Used Therein | |
| Trudell | Detection and identification of antibodies | |
| CN1282871A (en) | Technique and reagent kit for investigating blood platelet, blood type, antigen and antibody by microcolumn gel method | |
| CN1826526A (en) | Immunological assay system and method | |
| TW202014704A (en) | Immunoassay method and detection device for platelet antibody screening simultaneously with platelet cross-pairing selecting several different platelet antigen type combinations according to the type frequencies of human leukocyte antigens and human platelet antigens | |
| CN112285361B (en) | Agent for eliminating interference of anti-CD 38 monoclonal antibody medicine against human globulin detection | |
| TWI258011B (en) | Detecting method for blood cross-match test before blood transfusion | |
| Barron et al. | The use of polyethylene glycol (PEG) to enhance the adsorption of autoantibodies | |
| Habibi et al. | A Papain‐Bromelin‐Polybrene Four‐Channel Autoanalyzer System for Blood Group Antibody Screening: Analysis of 22,912 Sera | |
| Perrault et al. | Automated Red Cell Antibody Analysis. A Parallel Study: II. Identification of Serological Specificity | |
| CN101221181B (en) | Indirect method for detecting lymphocyte subgroup with mono-clone antibody SPA hematid rosette method | |
| US5143826A (en) | Method for identifying feline blood type B | |
| Tocci | Canine recipient screening |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061004 Termination date: 20171106 |